Key Metrics of Core Laboratories Inc.
Revenue$510M▲ 4.1% YoYFY 2023
Operating income$54.6M▲ 31.6% YoY
Net profit$36.7M▲ 88.5% YoY
Shareholders' equity$225M
Market cap$481MCLB · $10.49
Competitors10identified
About Core Laboratories Inc.
Sectors
Company details
- Founded
- 2023
- Listed
- NYSE: CLB (since 2023)
Operational Areas of Core Laboratories Inc.
Pharmaceuticals & Healthcare›Formulations & Contract Manufacturing
Company summary
Legal nameCore Laboratories Inc.
TickerCLB
ExchangeNYSE
CountryNetherlands
SEC CIK0001958086
Listed since2023
IndustryOilfield Services/Equipment
SectorPharmaceuticals & Healthcare · Formulations & Contract Manufacturing
Website—
US market & SEC filings
CLB · NYSE · SEC CIK 0001958086
Last price · 30 Oct 2026
$10.49
+1.55%
Market cap$481M
P/E13.6On FY 2023 diluted EPS
Volume977,004
SectorEnergyOilfield Services/Equipment
Country · IPONetherlandsListed 2023
CLB share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Core Laboratories Inc.
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | lilly.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | jjmt.com.tw | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | pg.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | merck.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | amgen.com | 1983 | United States | |
| Part of Gilead Sciences. | gilead.com | 1992 | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | abbott.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | pfizer.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | bms.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | marriott.com.cn | — | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.